"Via Oncology Pathways reflect five years of development by oncologists at UPMC (University of Pittsburgh Medical Center) and ongoing refinement by committees representing all oncology groups that have adopted the Pathways," said Kathleen Lokay, president, Via Oncology.
Every quarter, 15 disease-specific committees of academic and community-based physicians convene to review and revise the Pathways based on their independent evaluation of the most recent scientific evidence. After evaluating the findings of Phase III peer-reviewed studies, the disease experts on each committee define the single best treatment for each state and stage of disease according to a hierarchy of efficacy, toxicity and cost.
"We find that oncologists' treatment decisions reflect 75 percent to 85 percent concurrence with the Pathways," said Peter G. Ellis, M.D., medical director of Via Oncology and deputy director of clinical services, University of Pittsburgh Medical Center (UPMC) Cancer Centers. "But the flexibility to go off-Pathway is important. Scientific evidence informs and guides but cannot replace the clinical expertise of the individual physician who applies the evidence to the clinical state and condition of each patient."
Hematology-Oncology Associates of Northern New Jersey
Hematology-Oncology Associates of Northern New Jersey (HOANNJ), Morristown, N.J., is part of the Carol G. Simon Cancer Center at Morristown Memorial Hospital. HOANNJ offers the most current chemotherapy and biologic therapies. Our specialists -- Kenneth Adler, M.D., Gary Gerstein, M.D., Steven Papish, M.D., William DeRosa, D.O., Charles Farber, M.D., Ph.D., Michael Scola, M.D., Ellen Early, M.D., Stacey Leibowitz, M.D., Roshini George, D.O., David Gallinson
Copyright©2010 Vocus, Inc.
All rights reserved